Pharmacokinetics of glycopyrronium in uraemic patients

21Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We studied the pharmacokinetics of glycopyrronium 11 uraemic patients undergoing cadaveric renal transplantation and in seven ASA I control patients undergoing general surgery. Glycopyrronium 4 μg kg-1 was given i.v. before induction of anaesthesia. Blood and urine samples were collected for up to 24 h for measurement of glycopyrronium concentrations using a radioreceptor assay. Volume of distribution in the elimination phase (Vβ) was similar in both groups, the elimination half-life T12β was longer (P <0.05), area under the plasma concentration-time curve (AUC) larger (P <0.01) and plasma clearance (Cl) smaller (P < 0.01) in the uraemic patients. In 3 h, mean 0.7 (range 0-3) % and 50 (21-82) % of glycopyrronium was excreted in the urine in the uraemic and healthy patients, respectively (P <0.001). The 24-h renal excretion was 7 (0-25) % in uraernic and 65 (30-99) % in control patients (P <0.001). We conclude that the elimination of glycopyrronium is severely impaired in uraemic patients. © 1993 British Journal of Anaesthesia.

Cite

CITATION STYLE

APA

Kirvelä, M., Ali-melkkilä, T., Kaila, T., Iisalo, E., & Lindgren, L. (1993). Pharmacokinetics of glycopyrronium in uraemic patients. British Journal of Anaesthesia, 71(3), 437–439. https://doi.org/10.1093/bja/71.3.437

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free